Evaluating Emetine for Viral Outbreaks (EVOLVE)

• Status: Not yet recruiting
• Trial end date: 2025-06-14
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial (phase 2/phase 3) is to evaluate the efficacy and safety of emetine administered orally for symptomatic Covid-19 patients in patients ages 30 years and above. Participants will be asked to:

• Take Emetine 6mg orally for 10 consecutive days

• Be monitored by healthcare staff or self-monitor for daily vital signs and symptoms

• Undergo blood draws

Researchers will compare the control group given placebo medicine to assess if emetine improved the symptoms of Covid-19.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborators: Bharatpur Hospital Chitwan; Nepal Health Research Council; Rutgers University; Stony Brook University
• Treatments: Emetine

Criteria

Inclusion Criteria:

• 30 years of age or older at time of randomization

• RT-PCR positive for SARS-CoV-2 infection within ≤ 10 days of the screening visit.

• In addition to confirmed RT-PCR, symptomatic Covid-19 patients with at least two or more symptoms within 7 days of the screening visit: Cough, shortness of breath, fever/chills, sore throat, nausea, vomiting, diarrhea, fatigue, body aches, headache

• Ability to give informed consent (administered in local language)

Exclusion Criteria

• Asymptomatic Covid-19 patients

• Pregnant or breastfeeding woman

• Current or recent use of the study drug

• Known allergy to study drug

• Current or planned participation in another interventional trial in next 10 days.

• Critical Covid-19 patients (ARDS) at the time of screening.

• Patients needing intubation, mechanical ventilation, or ICU care at screening

• Patients with prior cardiac disease including cardiac dysrhythmias, heart failure, ischemic heart disease or cardiomyopathies.